|
1.
|
Artavanis-Tsakonas S, Rand MD and Lake RJ:
Notch signaling: cell fate control and signal integration in
development. Science. 284:770–776. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Blaumueller CM, Qi H, Zagouras P and
Artavanis–Tsakonas S: Intracellular cleavage of Notch leads to a
heterodimeric receptor on the plasma membrane. Cell. 90:281–291.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Davis RL and Turner DL: Vertebrate hairy
and enhancer of split related proteins: transcriptional repressors
regulating cellular differentiation and embryonic patterning.
Oncogene. 20:8342–8357. 2001. View Article : Google Scholar
|
|
4.
|
Ellisen LW, Bird J, West DC, Soreng AL,
Reynolds TC, Smith SD and Sklar J: TAN-1, the human homolog of the
Drosophila notch gene, is broken by chromosomal
translocations in T lymphoblastic neoplasms. Cell. 66:649–661.
1991.PubMed/NCBI
|
|
5.
|
Wang Z, Zhang Y, Li Y, Banerjee S, Liao J
and Sarkar FH: Down-regulation of Notch-1 contributes to cell
growth inhibition and apoptosis in pancreatic cancer cells. Mol
Cancer Ther. 5:483–493. 2006. View Article : Google Scholar
|
|
6.
|
Purow BW, Haque RM, Noel MW, Su Q, Burdick
MJ, Lee J, Sundaresan T, Pastorino S, Park JK, Mikolaenko I, Maric
D, Eberhart CG and Fine HA: Expression of Notch-1 and its ligands,
Delta-like-1 and Jagged-1, is critical for glioma cell survival and
proliferation. Cancer Res. 65:2353–2363. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Liu ZJ, Xiao M, Balint K, Smalley KS,
Brafford P, Qiu R, Pinnix CC, Li X and Herlyn M: Notch1 signaling
promotes primary melanoma progression by activating
mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt
pathways and up-regulating N-cadherin expression. Cancer Res.
66:4182–4190. 2006. View Article : Google Scholar
|
|
8.
|
Hubmann R, Schwarzmeier JD, Shehata M,
lgarth M, Duechler M, Dettke M and Berger R: Notch2 is involved in
the overexpression of CD23 in B-cell chronic lymphocytic leukaemia.
Blood. 99:3742–3747. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Haruki N, Kawaguchi KS, Eichenberger S,
Massion PP, Olson S, Gonzalez A, Carbone DP and Dang TP:
Dominant-negative Notch3 receptor inhibits mitogen-activated
protein kinase pathway and the growth of human lung cancers. Cancer
Res. 65:3555–3561. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Rizzo P, Miao H, D’Souza G, Osipo C, Yun
J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P,
Hicks C, Siziopikou K, Selvaggi S, Bashir A, Bhandari D, Marchese
A, Lendahl U, Qin JZ, Tonetti DA, Albain K, Nickoloff BJ and Miele
L: Cross-talk between notch and the estrogen receptor in breast
cancer suggests novel therapeutic approaches. Cancer Res.
68:5226–5235. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Nicolas M, Wolfer A, Raj K, Kummer JA,
Mill P, van Noort M, Hui CC, Clevers H, Dotto GP and Radtke F:
Notch1 functions as a tumor suppressor in mouse skin. Nat Genet.
33:416–421. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Dumortier A, Durham AD, Piazza MD,
Vauclair S, Koch U, Ferrand G, Ferrero I, Demehri S, Song LL, Farr
AG, Leonard WJ, Kopan R, Miele L, Hohl D, Finke D and Radtke F:
Atopic dermatitis-like disease and associated lethal
myeloproliferative disorder arise from loss of Notch signaling in
the murine skin. PloS One. 5:e92582010. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
O’Neill CF, Urs S, Cinelli C, Lincoln A,
Nadeau RJ, León R, Toher J, Mouta-Bellum C, Friesel RE and Liaw L:
Notch2 signaling induces apoptosis and inhibits human MDA-MB-231
xenograft growth. Am J Pathol. 171:1023–1036. 2007.PubMed/NCBI
|
|
14.
|
Tanimizu N and Miyajima A: Notch signaling
controls hepato-blast differentiation by altering the expression of
liver-enriched transcription factors. J Cell Sci. 117:3165–3174.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Nijjar S, Crosby HA, Wallace L, Hubscher
SG and Strain AJ: Notch receptor expression in adult human liver: a
possible role in bile duct formation and hepatic
neovascularisation. Hepatology. 34:1184–1192. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Jensen CH, Jauho EI, Santoni-Rugiu E,
Holmskov U, Teisner B, Tygstrup N and Bisgaard HC:
Transit-amplifying ductular (oval) cells and their hepatocytic
progeny are characterized by a novel and distinctive expression of
Delta-like protein/preadipocyte factor1/fetal antigen1. Am J
Pathol. 164:1347–1359. 2004. View Article : Google Scholar
|
|
17.
|
Kohler C, Bell AW, Bowen WC, Monga SP,
Fleig W and Michalopoulos GK: Expression of Notch-1 and its ligand
Jagged-1 in rat liver during liver regeneration. Hepatology.
39:1056–1065. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Giovannini C, Lacchini M, Gramantieri L,
Chieco P and Bolondi L: Notch3 intracellular domain accumulates in
HepG2 cell line. Anticancer Res. 26:2123–2127. 2006.PubMed/NCBI
|
|
19.
|
Gramantieri L, Giovannini C, Lanzi A,
Chieco P, Ravaioli M, Venturi A, Grazi GL and Bolondi L: Aberrant
Notch3 and Notch4 expression in human hepatocellular carcinoma.
Liver Int. 27:997–1007. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Cantarini MC, de la Monte SM, Pang M, Tong
M, D’Errico A, Trevisani F and Wands JR: Aspartyl-asparagyl β
hydroxylase over-expression in human hepatoma is linked to
activation of insulin-like growth factor and Notch signaling
mechanisms. Hepatology. 44:446–457. 2006.PubMed/NCBI
|
|
21.
|
Gao J, Chen C, Hong L, Wang J, Du Y, Song
J, Shao X, Zhang J, Han H, Liu J and Fan D: Expression of Jagged1
and its association with hepatitis B virus X protein in
hepatocellular carcinoma. Biochem Biophys Res Commun. 356:341–347.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Gao J, Song Z, Chen Y, Xia L, Wang J, Fan
R, Du R, Zhang F, Hong L, Song J, Zou X, Xu H, Zheng G, Liu J and
Fan D: Deregulated expression of Notch receptors in human
hepatocellular carcinoma. Dig Liver Dis. 40:114–121. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Ross DA and Kadesch T: The Notch
intracellular domain can function as a coactivator for LEF-1. Mol
Cell Biol. 21:7537–7544. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Kato H, Taniguchi Y, Kurooka H, Minoguchi
S, Sakai T, Nomura-Okazaki S, Tamura K and Honjo T: Involvement of
RBP-J in biological functions of mouse Notch1 and its derivatives.
Development. 124:4133–4141. 1997.PubMed/NCBI
|
|
25.
|
Struhl G and Adachi A: Nuclear access and
action of notch in vivo. Cell. 93:649–660. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Jundt F, Anagnostopoulos I, Förster R,
Mathas S, Stein H and Dörken B: Activated Notch1 signaling promotes
tumor cell proliferation and survival in Hodgkin and anaplastic
large cell lymphoma. Blood. 99:3398–4403. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Balint K, Xiao M, Pinnix CC, Soma A, Veres
I, Juhasz I, Brown EJ, Capobianco AJ, Herlyn M and Liu ZJ:
Activation of Notch1 signaling is required for
beta-catenin-mediated human primary melanoma progression. J Clin
Invest. 115:3166–3176. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Wang Z, Banerjee S, Li Y, Rahman KMW,
Zhang Y and Sarkar FH: Down-regulation of Notch-1 inhibits invasion
by inactivation of nuclear factor-κB, vascular endothelial growth
factor, and matrix metalloproteinase-9 in pancreatic cancer cells.
Cancer Res. 66:2778–2784. 2006.
|
|
29.
|
Qi R, An H, Yu Y, Zhang M, Liu S, Xu H,
Guo Z, Cheng T and Cao X: Notch1 signaling inhibits growth of human
hepatocellular carcinoma through induction of cell cycle arrest and
apoptosis. Cancer Res. 63:8323–8329. 2003.PubMed/NCBI
|
|
30.
|
Wang C, Qi R, Li N, Wang Z, An H, Zhang Q,
Yu Y and Cao X: Notch1 signaling sensitizes tumor necrosis
factor-related apoptosis-inducing ligand-induced apoptosis in human
hepato-cellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53
degradation and up-regulating p53-dependent DR5 expression. J Biol
Chem. 284:16183–16190. 2009. View Article : Google Scholar
|
|
31.
|
Miki A, Yano Y, Kato H, Seo Y, Kuriyama M,
Azuma T and Hayashi Y: Anti-tumor effect of pegylated interferon in
the rat hepatocarcinogenesis model. Int J Oncol. 32:603–608.
2008.PubMed/NCBI
|
|
32.
|
Ning L, Wentworth L, Chen H and Weber SM:
Down-regulation of Notch1 signaling inhibits tumor growth in human
hepatocellular carcinoma. Am J Transl Res. 1:358–366.
2009.PubMed/NCBI
|
|
33.
|
Wang XQ, Zhang W, Lui EL, Zhu Y, Lu P, Yu
X, Sun J, Yang S, Poon RT and Fan ST: Notch1-Snail1-E-cadherin
pathway in metastatic hepatocellular carcinoma. Int J Cancer.
131:E163–E172. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Gao J, Chen Y, Wu KC, Liu J, Zhao YQ, Pan
YL, Du R, Zheng GR, Xiong YM, Xu HL and Fan DM: RUNX3 directly
interacts with intracellular domain of Notch1 and suppresses Notch
signaling in hepatocellular carcinoma cells. Exp Cell Res.
316:149–157. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Giovannini C, Gramantieri L, Chieco P,
Minguzzi M, Lago F, Pianetti S, Ramazzotti E, Marcu KB and Bolondi
L: Selective ablation of Notch3 in HCC enhances doxorubicin’s death
promoting effect by a p53 dependent mechanism. J Hepatol.
50:969–979. 2009.PubMed/NCBI
|
|
36.
|
Rao SS, O’Neil J, Liberator CD, Hrdwick
JS, Dai X, Zhang T, Tyminski E, Yuan J, Kohl NE, Richon VM, van der
Ploeg LH, Carroll PM, Draetta GF, Look AT, Strack PR and Winter CG:
Inhibition of NOTCH signaling by gamma secretase inhibitor engages
the RB pathway and elicits cell cycle exit in T-cell acute
lymphoblastic leukemia cells. Cancer Res. 69:3060–3068. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Rasul S, Balasubramanian R, Filipović A,
Slade MJ, Yagüe E and Coombes RC: Inhibition of induces G2/M arrest
and triggers apoptosis in breast cancer cells. Br J Cancer.
100:1879–1888. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Nefedova Y, Sullivan DM, Bolick SC, Dalton
WS and Gabrilovich DI: Inhibition of Notch signaling induces
apoptosis of myeloma cells and enhances sensitivity to
chemotherapy. Blood. 111:2220–2229. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Weijzen S, Rizzo P, Braid M, Vaishnav R,
Jonkheer SM, Zlobin A, Osborne BA, Gottipati S, Aster JC, Hahn WC,
Rudolf M, Siziopikou K, Kast WM and Miele L: Activation of Notch-1
signaling maintains the neoplastic phenotype in human
Ras-transformed cells. Nat Med. 8:979–986. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Qin JZ, Stennett L, Bacon P, Bodner B,
Hendrix MJ, Seftor RE, Seftor EA, Margaryan NV, Pollock PM, Curtis
A, Trent JM, Bennett F, Miele L and Nickoloff BJ: p53-independent
NOXA induction overcomes apoptotic resistance of malignant
melanomas. Mol Cancer Ther. 3:895–902. 2004.PubMed/NCBI
|
|
41.
|
Deangelo DJ, Stone R, Silverman LB, Stock
W, Attar EC, Fearen I, Dallob A, Matthews C, Stone J, Freedman SJ
and Aster J: A phase I clinical trial of the notch inhibitor
MK-0752 in patients with T-cell acute lymphoblastic
leukemia/lymphoma (T-ALL) and other leukemias. In: Proceedings of
the ASCO Annual Meeting. J Clin Oncol. 24:65852006.
|
|
42.
|
Fouladi M, Stewart CF, Olson J, Wagner LM,
Onar-Thomas A, Kocak M, Packer RJ, Goldman S, Gururangan S, Gajjar
A, Demuth T, Kun LE, Boyett JM and Gilbertson RJ: Phase I trial of
MK-0752 in children with refractory CNS malignancies: a pediatric
brain tumor consortium study. J Clin Oncol. 29:3529–3534. 2011.
View Article : Google Scholar : PubMed/NCBI
|
